Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Gilead Sciences Inc

+ Add to Watchlist

GILD:US

100.6550 USD 0.7250 0.72%

As of 20:10:00 ET on 04/20/2015.

Snapshot for Gilead Sciences Inc (GILD)

Open: 102.2800 Day's Range: 100.4100 - 102.2800 Volume: 8,752,017
Previous Close: 101.3800 52wk Range: 69.4000 - 116.8300 1-Yr Rtn: +40.58%

Stock Chart for GILD

No chart data available.
  • GILD:US 100.6550
  • 1D
  • 1M
  • 1Y
101.3800
Interactive GILD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GILD

Current P/E Ratio (ttm) 13.6040
Estimated P/E(12/2015) 10.5211
Relative P/E vs. SPX 0.7339
Earnings Per Share (USD) (ttm) 7.3989
Est. EPS (USD) (12/2015) 9.5670
Est. PEG Ratio 0.6205
Market Cap (M USD) 149,277.67
Shares Outstanding (M) 1,483.06
30 Day Average Volume 10,834,732
Price/Book (mrq) 9.7810
Price/Sale (ttm) 6.1508
Dividend Indicated Gross Yield 1.71%
Cash Dividend (USD) 0.4300
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GILD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for GILD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

John C MartinChairman/CEOJohn F MilliganPresident/COO
Robin L WashingtonExec VP/CFOJohn G McHutchisonExec VP
More Company Profile & Key Executives for GILD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil